VIMTA LABS LTD.-$
P&L
Quarterly Standalone
vs Q4 FY25
Vimta Labs Reports Q1 FY26 Results: Total Income at Rs. 993 Mn, EBITDA Margin at 35.7%, PAT Margin at 19.0%
17 Jul 2025 · 17 Jul 2025, 03:10 pm
Summary
Vimta Labs Limited, a leading Contract Research and Testing Organisation, has announced its financial results for the quarter ended June 30, 2025. The company reported a total income of Rs. 993 Mn, a 31.4% YoY increase. The EBITDA margin stood at 35.7% and the PAT margin was at 19.0%.
Key Highlights
- 1
Q1 FY26 Total Income at Rs. 993 Mn, 31.4% YoY
- 2
EBITDA margins at 35.7%
- 3
PAT margin at 19.0%
- 4
Vimta completes a successful USFDA GCP inspection with zero Form 483 observations
- 5
Received letter of CGMP compliance from ANSM (EMA) during the quarter
- 6
Board approved a Bonus issue in the ratio of 1:1
- 7
Q1 FY26 EBITDA was Rs. 354 Mn; PAT was Rs. 189 Mn; Basic EPS was Rs. 4.2
Management Comments
Ms. Harita Vasireddi
Managing Director, Vimta Labs Limited
We are happy to report a revenue of Rs. 993 Mn for the quarter which was driven by pharmaceutical & food contract research and testing services that we provide. I am pleased with the consistent progress Vimta continues to make in strengthening its service portfolio and deepening customer relationships across sectors. Vimta completes a successful USFDA GCP inspection with zero Form 483 observations and received letter of CGMP compliance from ANSM (EMA) during the quarter. These outcomes are a reflection of Vimta’s strong commitment to quality, and scientific rigor. As a part of our efforts to enhance shareholder value, the Board has approved a Bonus issue in the ratio of 1:1, showcasing the company’s strong financial position, confidence in future growth, and commitment to rewarding its shareholders. Our focus remains on expanding our market reach and capabilities, fostering innovation, and creating sustainable long-term value for all our stakeholders.
Informational and educational content only. Not investment advice.